IPOX® CEO Josef Schuster shared insights with Bloomberg on the renewed optimism in Canada’s IPO market, highlighted by Groupe Dynamite Inc.’s C$300 million debut. Schuster emphasized the IPOX® Canada Opportunities Index's adaptability, which has delivered a strong 36% return this year, outperforming the S&P/TSX Composite Index. The index reflects growing investor confidence and emerging opportunities as Canada’s equity markets show signs of recovery.

IPOX® CEO Josef Schuster, portfolio manager and subadvisor to the Rakuten Global IPO Stock Fund, was featured in Japan’s Nikkei Newspaper (日本経済新聞), talking about Reddit’s impressive post-IPO growth, underscoring IPOX's focus on identifying high-potential companies in the evolving global IPO landscape.

IPOX® Research Analyst Dr. Lukas Muehlbauer commented on Septerna's upsized U.S. IPO as the Goldman Sachs-backed drug developer targets a valuation of $743.1 million. Septerna, originally planning to offer 10.9 million shares within a $15-$17 range, has now increased its offering to 15.3 million shares, pricing them at $18 each, to raise approximately $275 million. This move reflects positive investor sentiment for biotech IPOs, which have seen strong performances in the U.S. market this fall.

In a recent Reuters article, IPOX® CEO Dr. Josef Schuster highlighted the strategic timing behind Ingram Micro's return to the U.S. stock market, as the global technology distributor seeks a valuation of up to $5.42 billion. Schuster emphasized that private equity firms, like Ingram's backer Platinum Equity, are capitalizing on favorable market conditions, strong demand, and the opportunity to monetize their investments.

In a recent Reuters article, IPOX® Research Analyst Dr. Lukas Muehlbauer discussed the strong debut of Upstream Bio (UPB.O) in the IPO market. The Waltham, Massachusetts-based drug developer saw its stock rise 26.5% above the IPO price, giving it a market value of $1.05 billion.

In a recent Reuters article, IPOX® research analyst Lukas Muehlbauer highlighted strong institutional and retail demand for Bicara Therapeutics' IPO, which raised $315 million after upsizing twice. Bicara’s shares surged 46% in its debut, driven by confidence in its lead anti-cancer drug and notable backing from TPG and Biocon.

In Bloomberg, IPOX® CEO Josef Schuster discussed the resurgence of SPACs, noting $2 billion raised in August. He emphasized SPACs as a viable alternative to traditional IPOs for niche sectors, with renewed interest from sponsors. IPOX® tracks these trends as companies explore new public listing avenues.

Seeking Alpha published an analysis of the First Trust US Equity Opportunities ETF (FPX), which tracks our IPOX® 100 U.S. Index. The article states that "FPX is larger, more liquid, and better diversified" than its closest competitor.

In a CNN Arabic interview, IPOX® Schuster CEO Josef Schuster discussed China's reduction in U.S. debt holdings, highlighting its shift to gold and raw materials. He emphasized the need for the U.S. to manage its $34 trillion debt and rising servicing costs while expressing optimism about increased domestic investment in U.S. Treasuries.

IPOX® analyst Lukas Muehlbauer discusses that Reddit's IPO faces risks due to user skepticism over data commercialization and content moderation plans. The allocation of shares to active users without a holding period could increase volatility, but market timing and limited public shares might drive up the stock's value.

IPOX® Research Analyst Dr. Lukas Muehlbauer, featured in a Bloomberg article, discussed the potential impact of Reddit's WallStreetBets community on the company's post-IPO stock performance. He highlighted the community's negative sentiment regarding revenue and moderation concerns, and their potential to influence early trading, depending on their organization and activity.

Benzinga Newswire highlights that investors can gain exposure to Uber through the First Trust US Equity Opportunities ETF (FPX), which is based on the IPOX® 100 U.S. Index.

VettaFi highlights the IPOX®-based First Trust US Equity Opportunities ETF (FPX) as a way for investors to gain access to the latest newly listed companies.

John Authers' column in Bloomberg Opinion highlights the awakening of the US IPO market after a prolonged slumber. The article mentions the IPOX SPAC Index and the IPOX Composite US Index, both of which track the performance of new listings in the US.

In 2023, the IPO market showed signs of a rebound after the decline in 2022, reports IPOX® Schuster's Josef Schuster. The first nine months saw 76 IPOs raise nearly $15 billion, contrasting with 65 deals in 2022. Schuster anticipates a continued upward trend through 2024, emphasizing the volatile yet potentially rewarding nature of IPOs.

IPOX® CEO Josef Schuster discusses the challenges faced by Instacart in its upcoming IPO, emphasizing the need for a balance between robust valuation and initial shareholder satisfaction. Despite five consecutive quarters of profitability, Instacart's estimated worth has been a subject of debate, with significant interest from cornerstone investors. Schuster's insights highlight the broader challenges faced by gig-economy companies in a highly competitive market.

Looking at the underlying holdings of the First Trust US Equity Opportunities ETF (Symbol: FPX), analysts found that the implied analyst target price for the ETF based upon its underlying holdings is $110.22 per unit, a 24% upside over the next 12 months.

… For the First Trust US Equity Opportunities ETF (Symbol: FPX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $111.25 per unit.

With FPX trading at a recent price near $92.10 per unit, that means that analysts see 20.79% upside for this ETF